Trial Outcomes & Findings for Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST) (NCT NCT03963544)

Results Overview

time from the systemic treatment onset to the next treatment or death due to any cause, whichever came first.

Recruitment status

COMPLETED

Target enrollment

492 participants

Primary outcome timeframe

10 years

Results posted on

2025-12-10

Participant Flow

Participant milestones

Participant milestones
Measure	Participants With Metastatic Gastrointestinal Stromal Tumors (GIST) Participants with metastatic Gastrointestinal stromal tumors (GIST) treated in one of the three national coordinating centers from NETSARC (Institut Bergonié, Centre Léon Berard and Institut Gustave Roussy) from 1990 to 2018.
Overall Study STARTED	492
Overall Study COMPLETED	492
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Participants With Metastatic Gastrointestinal Stromal Tumors (GIST) n=492 Participants Participants with metastatic Gastrointestinal stromal tumors (GIST) treated in one of the three national coordinating centers from NETSARC (Institut Bergonié, Centre Léon Berard and Institut Gustave Roussy) from 1990 to 2018.
Age, Continuous	59 years n=492 Participants
Sex: Female, Male Female	200 Participants n=492 Participants
Sex: Female, Male Male	292 Participants n=492 Participants
Region of Enrollment France	492 participants n=492 Participants

PRIMARY outcome

Timeframe: 10 years

Population: Participants who received systemic treatment

time from the systemic treatment onset to the next treatment or death due to any cause, whichever came first.

Outcome measures

Outcome measures
Measure	Participants With Metastatic Gastrointestinal Stromal Tumors (GIST) n=461 Participants Participants with metastatic Gastrointestinal stromal tumors (GIST) treated in one of the three national coordinating centers from NETSARC (Institut Bergonié, Centre Léon Berard and Institut Gustave Roussy) from 1990 to 2018.
Time to Next Treatment (TNT)	26.7 months Interval 23.4 to 32.3

PRIMARY outcome

Timeframe: 10 years

the interval between the diagnosis of metastatic disease or the first-line systemic therapy onset and the time of death.

Outcome measures

Outcome measures
Measure	Participants With Metastatic Gastrointestinal Stromal Tumors (GIST) n=492 Participants Participants with metastatic Gastrointestinal stromal tumors (GIST) treated in one of the three national coordinating centers from NETSARC (Institut Bergonié, Centre Léon Berard and Institut Gustave Roussy) from 1990 to 2018.
Overall Survival (OS) Time	83.4 months Interval 72.7 to 97.9

SECONDARY outcome

Timeframe: At diagnosis of metastatic disease

Proportion of metastatic patients treated with a systemic therapy

Outcome measures

Outcome measures
Measure	Participants With Metastatic Gastrointestinal Stromal Tumors (GIST) n=492 Participants Participants with metastatic Gastrointestinal stromal tumors (GIST) treated in one of the three national coordinating centers from NETSARC (Institut Bergonié, Centre Léon Berard and Institut Gustave Roussy) from 1990 to 2018.
Treatment With a Systemic Therapy	461 Participants

SECONDARY outcome

Timeframe: 5 years

Proportion of participants included in a clinical trial (other than the present study) during the course of their metastatic disease

Outcome measures

Outcome measures
Measure	Participants With Metastatic Gastrointestinal Stromal Tumors (GIST) n=492 Participants Participants with metastatic Gastrointestinal stromal tumors (GIST) treated in one of the three national coordinating centers from NETSARC (Institut Bergonié, Centre Léon Berard and Institut Gustave Roussy) from 1990 to 2018.
Proportion of Participants Included in a Clinical Trial	269 Participants

Adverse Events

Participants With Metastatic Gastrointestinal Stromal Tumors (GIST)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 221 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Simone Mathoulin-Pélissier, Director of Clinical Trial Unit

Institut Bergonié, Comprehensive Cancer Center, Bordeaux, FR

Phone: +33 5 56 33 33 33

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place